PracticeVideosBlogFlashcardsEspañol
All Practice Exams

Free Practice Questions for Egyptian Board Internal Medicine

Exam-style questions and explanations by OpenExamPrep.

✓ No registration✓ No credit card
100+ Questions
100% Free

Loading practice questions...

Same family resources

Explore More Egyptian Board Specialty Certifications (البورد المصري)

Continue into nearby exams from the same family. Each card keeps practice questions, study guides, flashcards, videos, and articles in one place.

Egyptian Board — Anesthesia (Part 1 & 2)

Practice Questions

Egyptian Board — Cardiology (Part 1 & 2)

Practice Questions

Egyptian Board — Clinical Infectious Diseases (Part 1 & 2)

Practice Questions

Egyptian Board — Clinical Oncology (Part 1 & 2)

Practice Questions

Egyptian Board — Clinical Pathology (Part 1 & 2)

Practice Questions

Egyptian Board — Critical Care (Part 1 & 2)

Practice Questions

Sample Egyptian Board Internal Medicine Practice Questions

Try these sample questions to review concepts for the Egyptian Board Internal Medicine exam. Each question includes a detailed explanation. Start the interactive quiz above for the full 100+ question experience with AI tutoring.

1According to the Frank-Starling law of the heart, which physiological change primarily explains the initial increase in stroke volume when left ventricular end-diastolic volume rises?
A.Increased myofilament calcium sensitivity resulting from optimal overlap of actin and myosin filaments
B.Enhanced sympathetic beta-1 adrenergic phosphorylation of phospholamban in the sarcoplasmic reticulum
C.Direct augmentation of vagal parasympathetic tone dampening negative chronotropic slowing
D.Rapid upregulation of sarcoplasmic endoplasmic reticulum calcium ATPase (SERCA2a) protein expression
Explanation: The Frank-Starling mechanism states that increased end-diastolic volume stretches cardiac myocytes toward an optimal sarcomere length (approx 2.2 micrometers), augmenting actin-myosin overlap and troponin C calcium sensitivity. This mechanical length-dependent activation produces greater contractile force independent of autonomic nerve stimulation. In contrast, sympathetic inotropic stimulation acts through beta-1 receptor-mediated protein kinase A phosphorylation.
2Which set of physiologic triggers directly stimulates the exocytic release of renin from juxtaglomerular cells in the afferent glomerular arteriole?
A.Increased luminal sodium chloride delivery to the macula densa and high renal arterial perfusion pressure
B.Decreased renal perfusion pressure, low sodium chloride flux to the macula densa, and beta-1 adrenergic input
C.Hypervolemia, elevated atrial natriuretic peptide secretion, and renal alpha-2 adrenergic receptor stimulation
D.Angiotensin II feedback binding to AT1 receptors and severe hyperkalemia in renal interstitial fluid
Explanation: Renin secretion by juxtaglomerular granular cells is stimulated by three primary mechanisms: renal baroreceptor activation sensing decreased afferent arteriolar perfusion pressure, macula densa sensing of decreased tubular NaCl delivery/flux (via NKCC2 cotransporters and PGE2 signaling), and sympathetic stimulation via beta-1 adrenergic receptors. Conversely, high perfusion pressure, high tubular sodium, and angiotensin II exert negative feedback.
3Which combination of biochemical and physiological alterations shifts the oxyhemoglobin dissociation curve to the right, facilitating oxygen unloading at peripheral tissues?
A.Decreased temperature, systemic alkalosis, and reduced intracellular 2,3-bisphosphoglycerate concentration
B.Methemoglobin formation, carbon monoxide exposure, and hypothermia-induced enzyme inhibition
C.Elevated partial pressure of carbon dioxide, hydrogen ion accumulation (acidosis), and increased 2,3-BPG
D.Elevated fetal hemoglobin levels, severe hypocarbia, and acute hypophosphatemia
Explanation: A rightward shift of the oxyhemoglobin dissociation curve (the Bohr effect) lowers hemoglobin's affinity for oxygen, promoting O2 unloading in metabolically active tissues. This shift is driven by increased PaCO2, decreased pH (acidosis), elevated temperature, and increased red blood cell 2,3-bisphosphoglycerate (2,3-BPG). Conversely, hypothermia, alkalosis, and low 2,3-BPG shift the curve leftward.
4In the human gastrointestinal tract, what specific sequence of events is physiologically required for the normal absorption of dietary cobalamin (vitamin B12)?
A.Direct gastric mucosal uptake of unbound free cobalamin mediated by intrinsic factor transcytosis
B.Binding to transcobalamin II in the stomach followed by passive diffusion across the proximal jejunal enterocytes
C.Gastric binding to intrinsic factor, ileal proteolytic cleavage, and passive absorption across colonic colonocytes
D.Gastric haptocorrin binding, pancreatic protease cleavage in the duodenum, and ileal intrinsic factor-cubam uptake
Explanation: Dietary vitamin B12 is released by gastric acid and binds to salivary/gastric haptocorrin (R-binder), protecting it from gastric degradation. In the duodenum, pancreatic proteases degrade haptocorrin, allowing free B12 to complex with gastric parietal cell-derived intrinsic factor (IF). This stable IF-B12 complex resists digestion until it reaches the terminal ileum, where it undergoes receptor-mediated endocytosis via the cubam receptor complex.
5Which histopathologic pattern of tissue necrosis is classically observed in ischemic parenchymal infarction of solid visceral organs such as the myocardium, kidney, and spleen?
A.Coagulative necrosis with preservation of basic cellular outlines and protein denaturation
B.Liquefactive necrosis resulting in rapid enzymatic digestion and cystic cavity formation
C.Caseous necrosis with total loss of tissue architecture surrounded by granulomatous borders
D.Fibrinoid necrosis characterized by immune complex and fibrin deposition in arterial walls
Explanation: Ischemic infarction in solid organs (heart, kidney, spleen) produces coagulative necrosis. In this process, severe ischemia causes intracellular acidosis that denatures both structural proteins and enzymatic lysosomal proteins, preventing immediate autolysis and leaving 'ghost' cell outlines intact for several days. Liquefactive necrosis is the exception in brain tissue ischemia due to high lipid and hydrolytic enzyme content.
6A diagnostic tissue biopsy stained with Congo red dye demonstrates pathognomonic apple-green birefringence under polarized light microscopy. This optical property is attributable to which molecular characteristic?
A.Extensive alpha-helical protein conformation aligned randomly in amorphous ground substance
B.Cross-beta-pleated sheet tertiary structure aligned along linear, non-branching amyloid fibrils
C.High concentration of sulfated glycosaminoglycans forming amorphous extracellular aggregates
D.Covalent cross-linking of mature elastin fibers around small precapillary arterioles
Explanation: Amyloid fibrils are composed of misfolded protein monomers aggregated into an antiparallel cross-beta-pleated sheet tertiary structure. When Congo red dye molecules intercalate parallel to the long axis of these non-branching 7.5 to 10 nm fibrils, they produce anomalous optical dispersion, exhibiting pathognomonic apple-green birefringence under cross-polarized light. This property identifies amyloid deposition across AL, AA, and ATTR variants.
7A 65-year-old male with septic shock requires therapeutic drug monitoring. Drug X has a reported volume of distribution (Vd) of 0.08 L/kg. Based on this pharmacokinetic parameter, what is the primary anatomical distribution of Drug X in the body?
A.Extensive sequestration within peripheral adipose tissue and skeletal muscle cells
B.Uniform distribution throughout total body water including all intracellular compartments
C.Restriction largely to the intravascular plasma compartment with minimal tissue penetration
D.Selective accumulation within deep central nervous system and cerebrospinal fluid stores
Explanation: A very low volume of distribution (Vd of 0.04 to 0.1 L/kg, or roughly 3 to 7 liters in a 70 kg adult) indicates that the drug is largely confined to the vascular plasma compartment. This occurs with large, highly plasma protein-bound or hydrophilic molecules such as heparin and warfarin. In contrast, drugs with large Vd values (>1 L/kg, e.g., digoxin, amiodarone) distribute extensively into peripheral tissues.
8Which combination of antimicrobial agents acts as potent inhibitors of hepatic cytochrome P450 3A4 (CYP3A4), markedly elevating the serum concentration and toxicity risk of concurrent statins and calcineurin inhibitors?
A.Rifampin, phenobarbital, and carbamazepine
B.Amoxicillin-clavulanate, aztreonam, and cefepime
C.Gentamicin, amikacin, and colistin
D.Clarithromycin, itraconazole, and ritonavir
Explanation: Clarithromycin (a macrolide), itraconazole/ketoconazole (triazole antifungals), and ritonavir (protease inhibitor) are potent inhibitors of CYP3A4. Co-administration with CYP3A4 substrates such as simvastatin, atorvastatin, tacrolimus, or cyclosporine drastically reduces their first-pass metabolism and systemic clearance, leading to rhabdomyolysis or severe nephrotoxicity. Azithromycin does not significantly inhibit CYP3A4.
9Which therapeutic agent follows zero-order elimination kinetics at therapeutic or slightly supratherapeutic plasma levels due to saturation of its hepatic clearance enzymes?
A.Phenytoin
B.Gentamicin
C.Digoxin
D.Metoprolol
Explanation: Phenytoin exhibits Michaelis-Menten kinetics, meaning it follows first-order elimination at subtherapeutic concentrations but shifts to zero-order kinetics at usual therapeutic serum concentrations (10-20 mcg/mL). Under zero-order conditions, hepatic metabolic pathways are fully saturated, so a constant amount of drug is cleared per unit time regardless of concentration, predisposing patients to steep, non-linear toxicity surges upon small dose increments.
10A 38-year-old female presents with bilateral flank masses, refractory hypertension, and microscopic hematuria. Genetic evaluation establishes a diagnosis of autosomal dominant polycystic kidney disease (ADPKD). What genetic defect accounts for the majority of ADPKD cases?
A.Mutations in the PKHD1 gene on chromosome 6 encoding the fibrocystin protein
B.Mutations in the PKD1 gene on chromosome 16 encoding the polycystin-1 protein
C.Mutations in the COL4A5 gene on the X chromosome encoding alpha-5 type IV collagen
D.Deletions involving the VHL tumor suppressor gene located on chromosome 3p
Explanation: Approximately 78-85% of ADPKD cases result from mutations in the PKD1 gene located on chromosome 16p13.3, which encodes polycystin-1, an integral membrane protein regulating primary cilia function and intracellular calcium. Mutations in PKD2 (chromosome 4q21, encoding polycystin-2) account for roughly 15% of cases and generally present with a milder, later-onset clinical phenotype.

About the Egyptian Board Internal Medicine Exam

The Egyptian Board in Internal Medicine is the premier national specialty certification conferred by the Egyptian Health Council under Law No. 12 of 2022. It assesses mastery of applied basic medical sciences (Part 1), comprehensive clinical internal medicine diagnosis and pharmacotherapy (Part 2), and advanced clinical bedside and OSCE performance (Part 3). This practice question bank is an English-language study aid focused on written cognitive knowledge, diagnostic test interpretation, and guideline-directed clinical management.

Exam sponsor: Egyptian Health Council — Egyptian Board. The requirements and fees below concern the certification or admission exam, separate from our free practice resources.

Assessment

The Egyptian Board in Internal Medicine (البورد المصري في الأمراض الباطنة) is governed by the Egyptian Health Council (EHC) under Law No. 12 of 2022 and Prime Ministerial Decree No. 3798 of 2023. The certification pathway consists of three examination tiers: Part One (applied basic medical sciences: physiology, pathology, clinical pharmacology, medical genetics, and biostatistics, held in March and August); Part Two (advanced clinical internal medicine single-best-answer written MCQs, held in April and September); and Part Three (clinical OSCE, oral examinations, and structured long/short clinical cases, held in December and January). Written papers are scored using psychometric standard-setting methods (Angoff/Modified Angoff or Hofstee), while Part Three uses borderline regression.

Time Limit

Varies by examination part

Passing Score

Set by psychometric standard-setting (Angoff/Hofstee method); no fixed percentage published

Exam / Certification Fees

Set periodically by the Egyptian Health Council under Prime Ministerial Decree No. 3798 of 2023 for each examination part (separate fees apply for Part One, Part Two, and Part Three).

Exam sponsor website

Reported exam pass rate: Determined annually through criterion-referenced standard-setting committees; not publicly released as a fixed time-series.. EHC establishes passing thresholds for each sitting using psychometric standard-setting panels rather than arbitrary numerical cutoffs. Exam sponsor website

Fees, eligibility, and exam policies can change. Confirm them with the exam sponsor before applying or paying.

Our practice resources: topics covered

We aim to reflect publicly available exam outlines and topic information in our study resources. Coverage, format, and difficulty may differ from the actual exam, and we cannot guarantee that every detail is accurate or current. Confirm exam requirements, fees, and policies with the official exam sponsor.

20% of exam

Applied Basic Medical Sciences (Part One)

Cardiovascular, respiratory, and renal physiology, cellular pathology, clinical pharmacology and pharmacokinetics, genetic transmission patterns, and medical biostatistics.

12% of exam

Cardiovascular Medicine

Acute coronary syndromes, chronic coronary disease, heart failure with reduced and preserved ejection fraction, valvular disease, supraventricular and ventricular arrhythmias, and hypertension.

12% of exam

Gastroenterology and Hepatology

Complications of liver cirrhosis, acute and chronic viral hepatitis, portal hypertension, acute pancreatitis, peptic ulcer disease, inflammatory bowel disease, and malabsorption syndromes.

10% of exam

Pulmonology and Critical Care Medicine

Community-acquired and hospital-acquired pneumonia, COPD exacerbations, severe asthma, pulmonary thromboembolism, pleural effusions, ARDS, and arterial blood gas analysis.

10% of exam

Endocrinology, Diabetes, and Metabolism

Type 1 and Type 2 diabetes management, diabetic ketoacidosis, hyperosmolar hyperglycemic state, hyper- and hypothyroidism, adrenal insufficiency, Cushing syndrome, and pituitary adenomas.

10% of exam

Nephrology and Acid-Base Disorders

Acute kidney injury classification and management, chronic kidney disease progression and complications, primary and secondary glomerulonephritis, nephrotic syndrome, and fluid-electrolyte imbalances.

8% of exam

Hematology and Medical Oncology

Diagnostic workup of anemias, thrombocytopenia, coagulopathies, acute and chronic leukemias, non-Hodgkin and Hodgkin lymphomas, multiple myeloma, and febrile neutropenia.

8% of exam

Infectious Diseases

Sepsis-3 guidelines and septic shock resuscitation, healthcare-associated infections, tuberculosis diagnosis and therapy, HIV/AIDS opportunistic diseases, infective endocarditis, and fever of unknown origin.

5% of exam

Rheumatology and Clinical Immunology

Systemic lupus erythematosus, rheumatoid arthritis, seronegative spondyloarthropathies, systemic sclerosis, inflammatory myopathies, gout, and systemic necrotizing vasculitides.

5% of exam

Neurology

Acute ischemic stroke thrombolysis and thrombectomy indications, intracranial hemorrhage, status epilepticus, acute meningitis and encephalitis, myasthenia gravis, Guillain-Barré syndrome.

Preparing for the Egyptian Board Internal Medicine Exam

What You Need to Know

  • Passing score: Set by psychometric standard-setting (Angoff/Hofstee method); no fixed percentage published
  • Assessment: The Egyptian Board in Internal Medicine (البورد المصري في الأمراض الباطنة) is governed by the Egyptian Health Council (EHC) under Law No. 12 of 2022 and Prime Ministerial Decree No. 3798 of 2023. The certification pathway consists of three examination tiers: Part One (applied basic medical sciences: physiology, pathology, clinical pharmacology, medical genetics, and biostatistics, held in March and August); Part Two (advanced clinical internal medicine single-best-answer written MCQs, held in April and September); and Part Three (clinical OSCE, oral examinations, and structured long/short clinical cases, held in December and January). Written papers are scored using psychometric standard-setting methods (Angoff/Modified Angoff or Hofstee), while Part Three uses borderline regression.
  • Time limit: Varies by examination part
  • Exam / certification fees: Set periodically by the Egyptian Health Council under Prime Ministerial Decree No. 3798 of 2023 for each examination part (separate fees apply for Part One, Part Two, and Part Three). Official sources

Using Our Practice Resources

  • Work through all 100 available questions
  • Review every answer and explanation
  • Track weak areas and revisit them
  • Use our AI tutor for tough concepts

Egyptian Board Internal Medicine: Suggested Study Strategy

1Master the applied basic sciences for Part One by integrating physiology, pathophysiology, and pharmacology into clinical mechanisms rather than memorizing isolated facts.
2Focus Part Two preparation on clinical guidelines and diagnostic algorithms from EHC reference frameworks and international clinical societies (ESC, KDIGO, GOLD, ADA, EASL).
3Pay meticulous attention to first-line pharmacotherapy choices, contraindications, and drug-drug interactions in multi-morbid internal medicine patients.
4Review high-yield electrocardiograms, arterial blood gas profiles, chest radiographs, and laboratory diagnostic panels frequently tested in clinical problem-solving.
5Practice timed single-best-answer MCQs to build speed and avoid second-guessing on clinical vignettes with subtle discriminators.

Frequently Asked Questions

What is the official structure of the Egyptian Board in Internal Medicine?

The Egyptian Board certification under the Egyptian Health Council (EHC) consists of three examination tiers: Part One evaluates applied basic sciences (physiology, pathology, pharmacology, genetics, and statistics); Part Two assesses advanced clinical internal medicine through single-best-answer written MCQs; and Part Three consists of clinical OSCE, oral examinations, and patient case assessments.

How are the passing scores determined for Egyptian Board examinations?

The Egyptian Health Council employs psychometric standard-setting methodologies rather than arbitrary percentage cutoffs. Written papers in Part One and Part Two are set using Angoff, Modified Angoff, or Hofstee methods, while the Part Three clinical OSCE uses the Borderline Regression Method.

Does this question bank simulate the Part Three clinical examination?

No. Part Three of the Egyptian Board is a live clinical examination consisting of OSCE stations, oral viva boards, and physical patient examinations. This 100-question multiple-choice question bank is designed as an English-language study aid for the cognitive knowledge, diagnostic test interpretation, and clinical management required in Part One and Part Two.

What legal framework governs the Egyptian Board examinations?

The Egyptian Board (formerly the Egyptian Fellowship) is governed by Egyptian Health Council Law No. 12 of 2022 and its Executive Regulations promulgated under Prime Ministerial Decree No. 3798 of 2023, unifying professional health training and certification under the EHC.

When are the Egyptian Board internal medicine examinations held?

Typically, Part One written examinations are scheduled in March and August; Part Two clinical written examinations are held in April and September; and Part Three clinical/OSCE examinations are administered in December and January.